Skip to main content
DNLI
NASDAQ Life Sciences

FDA Approves Denali's AVLAYAH for Hunter Syndrome, First Brain-Penetrant Therapy in 20 Years

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$21.925
Mkt Cap
$3.477B
52W Low
$10.57
52W High
$23.77
52W Position info
107% above low
Off High info
7.8% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

DNLI has more than doubled off its 52-week low of $10.57.

Summary

Denali Therapeutics has secured accelerated FDA approval for AVLAYAH™ (tividenofusp alfa-eknm) for the treatment of neurologic manifestations of Hunter Syndrome (MPS II). This marks a significant breakthrough, being the first new FDA-approved treatment for the condition in nearly two decades and the first biologic specifically designed to cross the blood-brain barrier for this indication. The approval also comes with a Rare Pediatric Disease Priority Review Voucher. This milestone validates Denali's proprietary TransportVehicle™ platform and is expected to open a new, material revenue stream for the company, addressing a critical unmet medical need. Investors will now focus on the commercial launch and the ongoing Phase 2/3 COMPASS study, which is designed to provide confirmatory evidence for continued approval.

At the time of this announcement, DNLI was trading at $21.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $10.57 to $23.77. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

DNLI - Latest Insights

DNLI
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.35
Real-time Price: $19.17 info
Change: -$1.19 (-6%) info
Market Cap: $3.072B info
DNLI
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.45
Real-time Price: $19.17 info
Change: -$0.285 (-1%) info
Market Cap: $3.072B info
DNLI
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.45
Real-time Price: $19.17 info
Change: -$0.285 (-1%) info
Market Cap: $3.072B info
DNLI
Aug 06, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $25.10
Real-time Price: $19.17 info
Change: -$5.94 (-24%) info
Market Cap: $3.072B info
DNLI
Jun 18, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.89
Real-time Price: $19.17 info
Change: -$4.73 (-20%) info
Market Cap: $3.072B info